By Mitul Agarwal, B.Pharm, MBA. Published October 2026.
The drug substance is the active ingredient itself, the API: metformin hydrochloride powder, for example. The drug product is the finished medicine a patient actually takes, such as metformin 500 mg tablets, made by combining the drug substance with excipients, turning it into a dosage form and packing it. The two are often made at different sites, always under different GMP rules, and they are documented in different parts of a registration dossier.
The distinction sounds academic until you need to register a product, qualify a supplier or work out why a regulator is asking about a factory you have never heard of. Then it becomes very practical indeed.
How regulators define them
The drug substance is the active ingredient intended to produce the medicine's pharmacological effect. US regulations define it in exactly those terms and specifically exclude the intermediates used to make it. ICH guidelines use "drug substance" and "active pharmaceutical ingredient (API)" to mean the same thing, and in India the same material is commonly called a bulk drug.
The drug product is the finished dosage form, whether a tablet, capsule, solution or injection, that contains the drug substance, usually together with other ingredients. WHO calls it a finished pharmaceutical product (FPP). Traders tend to say FDF, for finished dosage form, or simply "formulation", and EU law calls it a medicinal product.
Side by side
| Drug substance (API) | Drug product (FDF) | |
|---|---|---|
| What it is | The active ingredient, usually a powder or crystalline solid (for biologics, a purified protein solution) | The finished medicine: tablets, capsules, syrups, vials, inhalers, patches |
| How it is made | Chemical synthesis, fermentation, extraction or, for biologics, cell culture and purification | Formulation: blending with excipients, granulation, compression, filling, sterilisation, packing |
| Where it is made | API plants | Formulation plants, often owned by a different company |
| GMP standard | ICH Q7 (EU GMP Part II) | EU GMP Part I; US 21 CFR 210 and 211; WHO GMP for FPPs |
| Dossier section (CTD) | Module 3.2.S | Module 3.2.P |
| Regulatory file | US DMF (Type II), CEP or ASMF | The product's marketing authorisation (NDA, ANDA, MA) |
| Specification guideline | ICH Q6A (chemicals) or Q6B (biologics): identity, assay, impurities, residual solvents, particle size, polymorph | ICH Q6A or Q6B: identity, assay, dissolution, uniformity, impurities, microbial limits, sterility where relevant |
| Stability | ICH Q1A (chemicals) or Q5C (biologics) studies on the API in its container; gives a retest period | ICH Q1A or Q5C studies on the product in its final pack; gives the shelf life |
| Who buys it | Formulation manufacturers and CDMOs | Importers, distributors, hospitals, governments and pharmacies |
The chain that connects them
Drug substance and drug product are really two points on one supply chain. It starts with a key starting material, the chemical building block from which the registered API process begins. That material is converted, step by step, through a series of intermediates until the final reaction and purification produce the drug substance, which is tested and released against its specification. A formulation plant then combines it with excipients (fillers, binders, disintegrants, lubricants, coatings, solvents, preservatives) and turns it into the drug product, which is packed and released in its turn.
API GMP under ICH Q7 applies from the point the starting material enters the registered process, and becomes stricter towards the final steps. Because each link is named in the dossier, a change anywhere along the chain, such as a new starting-material supplier or a new API site, can trigger a regulatory variation for the finished product.
Biologics: the same words, a different picture
For a monoclonal antibody or a vaccine, the drug substance is the purified bulk protein produced by cell culture. The drug product is that protein after it has been formulated, filled into vials or prefilled syringes and labelled. The two steps often take place at different sites, and fill-finish is one of the most widely outsourced parts of biologics manufacturing. Our guide to injectable and sterile CDMOs covers what to check at a fill-finish partner.
Why buyers should care
If you are buying a finished product, ask where its API comes from as well as where the product itself is made. The importing regulator will usually ask the same question, because the API source is named in the dossier and changing it needs a variation.
If you are buying an API, look at its documents: a DMF, CEP or ASMF, the GMP certificate of the API site and, for export to the EU, the written confirmation from the exporting country's regulator (unless that country is on the EU's equivalence list). Our guide to CEP, DMF and ASMF explains which one you need, and our explainer on hydrochloride versus base covers why the exact salt form matters.
If you are registering a product, the dossier needs both halves: section 3.2.S for the drug substance, often supported by the API maker's DMF or CEP, and section 3.2.P for the drug product. Our guide to CTD and ACTD shows how the formats differ.
And if you are comparing two suppliers of the "same" product, remember that the same API at the same strength does not make the same medicine. Excipients, process and packaging all differ, which is exactly why regulators ask for bioequivalence data for most oral generics.
Related explainers
For the basics of the active ingredient itself, read what an API is and how it is bought. If you are choosing a partner to develop or make your product, CRO vs CDMO vs CMO explains who does what.
How PharmaTradz can help
PharmaTradz connects buyers with manufacturers of both APIs and finished formulations. Tell us whether you need the drug substance or the drug product, the grade or strength, and the market it is for, and we will share each supplier's document status before you commit. Our documentation and quality pack collects GMP, CoPP and CoA documents up front, or you can simply send us an RFQ. Terms such as KSM, CoA and CoPP are explained in our six-language pharma glossary.
Frequently Asked Questions(FAQs)
Is a drug substance the same as an API?
Yes. ICH guidelines use "drug substance" and "active pharmaceutical ingredient (API)" to mean the same thing. In India the same material is often called a bulk drug.
What is an example of a drug substance and a drug product?
Paracetamol powder made at an API plant is the drug substance. Paracetamol 500 mg tablets, made from that powder with excipients and packed in blisters, are the drug product.
Which part of the CTD covers each?
Module 3.2.S covers the drug substance and Module 3.2.P covers the drug product. The 3.2.S section is often supported by the API maker's DMF, CEP or ASMF.
Do drug substance and drug product follow the same GMP rules?
No. API manufacture follows ICH Q7 (EU GMP Part II), while finished products follow EU GMP Part I, US 21 CFR 210 and 211, or WHO GMP for finished pharmaceutical products.
What is the drug substance for a biologic?
The purified bulk protein produced by cell culture. The drug product is that protein once it has been formulated, filled into vials or syringes and labelled.
